Clinical Effectiveness Assessment of VeriStrat® Testing and Validation of Immunotherapy Tests in NSCLC Subjects

The primary purpose of this observational study is to assess the physician's clinical

practice patterns while using VeriStrat testing in subjects with NSCLC whose tumors are

epidermal growth factor receptor (EGFR) wild-type (negative) or have unknown EGFR

mutational status. This study will also attempt to further validate that VeriStrat test

results stratify subjects by clinical outcomes in the real world, uncontrolled clinical

setting while exploring whether certain therapeutic approaches may yield opportunities

for further study.

Predictive tests that aid physician therapeutic decision making are critical for

optimizing subject outcomes while minimizing toxicity and associated treatment costs.

This study will provide data for the validation of immunotherapy tests currently being

developed. Immunotherapy mechanisms are dependent upon the interactions between the

tumor, tumor microenvironment, and the patient immune system. As such, a successful

predictive test will reflect the complex interplay between tumor and host. The

multivariate tests from Biodesix have the advantage of being able to assess this complex

biology.

The information gained from this research will not only guide the adoption of the

VeriStrat test and inform medical decision making, including treatment choice, but will

allow the validation of additional mass-spectrometry-based proteomic tests.